Bukowski R M
Experimental Therapeutics Program, Cleveland Clinic Cancer Center, OH 44195.
Semin Oncol. 1994 Aug;21(4 Suppl 7):96-9.
In recent years, biologic response modifiers, including recombinant cytokines and hematopoietic growth factors, have been used to treat patients with refractory hematologic malignancies and solid tumors, as well as chemotherapy-associated myelosuppression and thrombocytopenia and treatment- and/or malignancy-related anemia. Various cytokines appear to be effective in patients with hematologic malignancies, but long-term and durable responses in the salvage setting are rare. In patients with solid tumors, such as renal cell carcinoma, malignant melanoma, and colorectal cancer, cytokines may have a limited role in primary therapy but are of little value in salvage therapy. Complications of malignancy and antineoplastic therapy are widely treated with hematopoietic growth factors, like granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, and more recently the interferons and interleukins have demonstrated a potential role in this setting.
近年来，生物反应调节剂，包括重组细胞因子和造血生长因子，已被用于治疗难治性血液系统恶性肿瘤和实体瘤患者，以及化疗相关的骨髓抑制、血小板减少症和治疗及/或恶性肿瘤相关的贫血。各种细胞因子似乎对血液系统恶性肿瘤患者有效，但在挽救治疗中出现长期持久反应的情况很少见。在实体瘤患者中，如肾细胞癌、恶性黑色素瘤和结直肠癌患者，细胞因子在一线治疗中的作用可能有限，但在挽救治疗中价值不大。恶性肿瘤和抗肿瘤治疗的并发症广泛使用造血生长因子进行治疗，如粒细胞集落刺激因子和粒细胞巨噬细胞集落刺激因子，最近干扰素和白细胞介素在这种情况下也显示出潜在作用。
